Natural products derived from traditional Chinese medicine as novel inhibitors of the epidermal growth factor receptor

Combinatorial Chemistry and High Throughput Screening

Volumn 13, Issue 10, 2010, Pages 849-854

  Sertel, Serkan ^a,b   Plinkert, Peter K ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Cancer; Drug resistance; EGFR tyrosine kinase inhibitor; Epidermal growth factor receptor (EGFR); Medicinal plant; Natural product

Indexed keywords

ARTEMISININ; ARTESUNATE; C MET KINASE INHIBITOR; CAMPTOTHECIN; CEPHALOTAXINE; CISPLATIN; DICENTRINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HOMOHARRINGTONINE; HONOKIOL; MAGNOLOL; NATURAL PRODUCT; ORIDONIN; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; SHIKONIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHILL; CHINESE MEDICINE; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FEVER; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUMOR BIOPSY; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUGS, CHINESE HERBAL; HUMANS; MEDICINE, CHINESE TRADITIONAL; NEOPLASMS; PLANTS, MEDICINAL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79951646318     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/138620710793360266     Document Type: Article

References (59)

1. Ono, M.; Kuwano, M. Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin. Cancer Res., 2006, 12(24), 7242-7251. (Pubitemid 46095395)
2. Yarden, Y.; Sliwkowski, M.X. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol., 2001, 2(2), 127-137. (Pubitemid 33674041)
3. Wang, K.; Yamamoto, H.; Chin, J.R.; Werb, Z.; Vu, T.H. Epidermal growth factor receptor-deficient mice have delayed primary endochondral ossification because of defective osteoclast recruitment. J. Biol. Chem., 2004, 279(51), 53848-53856. (Pubitemid 40051894)
4. Herbst, R.S.; Langer, C.J. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol., 2002, 29(1 Suppl 4), 27-36. (Pubitemid 34226516)
5. Ethier, S.P. Signal transduction pathways: the molecular basis for targeted therapies. Semin. Radiat. Oncol., 2002, 12(3 Suppl 2), 3-10. (Pubitemid 34920086)
6. Slamon, D.J.; Clark, G.M.; Wong, S.G.; Levin, W.J.; Ullrich, A.; McGuire, W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235(4785), 177-182. (Pubitemid 17231334)
7. Konkimalla, V.B.; Suhas, V.L.; Chandra, N.R.; Gebhart, E.; Efferth, T. Diagnosis and therapy of oral squamous cell carcinoma. Expert Rev. Anticancer Ther., 2007, 7(3), 317-329. (Pubitemid 46488337)
8. Perea, S.; Hidalgo, M. Predictors of sensitivity and resistance to epidermal growth factor receptor inhibitors. Clin. Lung Cancer, 2004, 6 Suppl 1, S30-34.
9. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70(3), 461-477. (Pubitemid 46595760)
10. Tang, W.; Hemm, I.; Bertram, B. Recent development of antitumor agents from chinese herbal medicines; part I. Low molecular compounds. Planta Med., 2003, 69(2), 97-108. (Pubitemid 36384491)
11. Tang, W.; Hemm, I.; Bertram, B. Recent development of antitumor agents from Chinese herbal medicines. Part II. High molecular compounds(3). Planta Med., 2003, 69(3), 193-201. (Pubitemid 36470121)
12. Efferth, T.; Volm, M. Reversal of doxorubicin-resistance in sarcoma 180 tumor cells by inhibition of different resistance mechanisms. Cancer Lett., 1993, 70(3), 197-202. (Pubitemid 23238686)
13. Efferth, T.; Volm, M. Immunocytochemical detection of oncoproteins in animal and human tumor lines with acquired or inherent multidrug resistance. Cancer Detect Prev., 1992, 16(4), 237-243.
14. Volm, M.; Koomagi, R.; Efferth, T. Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics, 2004, 1, 157-166.
15. el-Deiry, W. S. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr. Opin. Oncol., 1997, 9(1), 79-87. (Pubitemid 27142557)
16. Volm, M.; Efferth, T.; Mattern, J. Oncoprotein (c-myc, c-erbB1, cerbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res., 1992, 12(1), 11-20.
17. Efferth, T.; Volm, M. Protein expression profiles indicative for drug resistance of kidney carcinoma. Cancer Genomics Proteomics, 2004, 1, 17-22.
18. Maher, E.A.; Furnari, F B.; Bachoo, R.M.; Rowitch, D.H.; Louis, D.N.; Cavenee, W.K.; DePinho, R.A. Malignant glioma: genetics and biology of a grave matter. Genes Dev., 2001, 15, (11), 1311-1333. (Pubitemid 32524640)
19. Nagane, M.; Huang, H.J.; Cavenee, W. K. Advances in the molecular genetics of gliomas. Curr. Opin. Oncol., 1997, 9(3), 215-222. (Pubitemid 27290443)
20. Nagane, M.; Narita, Y.; Mishima, K.; Levitzki, A.; Burgess, A. W.; Cavenee, W. K.; Huang, H. J. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J. Neurosurg., 2001, 95(3), 472-479. (Pubitemid 32781500)
21. Nagane, M.; Levitzki, A.; Gazit, A.; Cavenee, W.K.; Huang, H.J. Drug resistance of human glioblastoma cells conferred by a tumorspecific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc. Natl. Acad. Sci. USA, 1998, 95(10), 5724-5729.
22. Huang, P.H.; Mukasa, A.; Bonavia, R.; Flynn, R.A.; Brewer, Z.E.; Cavenee, W.K.; Furnari, F.B.; White, F. M. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl. Acad. Sci. USA, 2007, 104(31), 12867-12872. (Pubitemid 47255246)
23. Lee, D.H.; Szczepanski, M. J.; Lee, Y.J. Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells. J. Cell Biochem., 2009, 106(6), 1113-1122.
24. Han, J. Traditional Chinese medicine and the search for new antineoplastic drugs. J. Ethnopharmacol., 1988, 24(1), 1-17.
25. Efferth, T.; Davey, M.; Olbrich, A.; Rucker, G.; Gebhart, E.; Davey, R. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrugresistant human CCRF-CEM leukemia cells. Blood Cells Mol. Dis., 2002, 28(2), 160-168. (Pubitemid 34743750)
26. Efferth, T.; Sauerbrey, A.; Halatsch, M.E.; Ross, D.D.; Gebhart, E. Molecular modes of action of cephalotaxine and homoharringtonine from the coniferous tree Cephalotaxus hainanensis in human tumor cell lines. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367(1), 56-67. (Pubitemid 36207682)
27. Klayman, D.L. Qinghaosu (artemisinin): an antimalarial drug from China. Science, 1985, 228(4703), 1049-1055. (Pubitemid 15227365)
28. Efferth, T. Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin - from bench to bedside. Planta Med., 2007, 73(4), 299-309. (Pubitemid 46910410)
29. Efferth, T.; Giaisi, M.; Merling, A.; Krammer, P. H.; Li-Weber, M. Artesunate induces ROS-mediated apoptosis in doxorubicinresistant T leukemia cells. PLoS One., 2007, 2(1), e693.
30. Efferth, T.; Li, P.C.; Konkimalla, V.S.; Kaina, B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007, 13(8), 353-361. (Pubitemid 47126989)
31. Mitsudomi, T.; Yatabe, Y. Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer. FEBS J., 2010, 277(2), 301-308.
32. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA Cancer J. Clin., 2009, 59(4), 225-249.
33. Volm, M.; Koomagi, R.; Mattern, J.; Efferth, T. Protein expression profiles indicative for drug resistance of non-small cell lung cancer. Br. J. Cancer, 2002, 87(3), 251-257.
34. Efferth, T. The human ATP-binding cassette transporter genes: from the bench to the bedside. Curr. Mol. Med., 2001, 1(1), 45-65. (Pubitemid 33772969)
35. Volm, M.; Koomagi, R.; Efferth, T. Prediction of drug sensitivity and resistance of cancer by protein expression profiling. Cancer Genomics Proteomics, 2004, 1, 157-166.
36. Efferth, T.; Volm, M. Pharmacogenetics for individualized cancer chemotherapy. Pharmacol. Ther., 2005, 107(2), 155-176. (Pubitemid 40910039)
37. Volm, M.; Koomagi, R.; Mattern, J.; Efferth, T. Expression profile of genes in non-small cell lung carcinomas from long-term surviving patients. Clin. Cancer Res., 2002, 8, 1843-1848. (Pubitemid 34633744)
38. Volm, M.; Kastel, M.; Mattern, J.; Efferth, T. Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas. Cancer, 1993, 71(12), 3981-3987. (Pubitemid 23172981)
39. Shepherd, F.A.; Rodrigues Pereira, J.; Ciuleanu, T.; Tan, E.H.; Hirsh, V.; Thongprasert, S.; Campos, D.; Maoleekoonpiroj, S.; Smylie, M.; Martins, R.; van Kooten, M.; Dediu, M.; Findlay, B.; Tu, D.; Johnston, D.; Bezjak, A.; Clark, G.; Santabarbara, P.; Seymour, L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med., 2005, 353(2), 123-132. (Pubitemid 41058344)
40. Chen, L.F.; Cohen, E.E.; Grandis, J.R. New strategies in head and neck cancer: understanding resistance to epidermal growth factor receptor inhibitors. Clin. Cancer Res., 2010, 16(9), 2489-2495.
41. Dobrossy, L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis. Rev., 2005, 24(1), 9-17. (Pubitemid 40584773)
42. Kupferman, M.E.; Myers, J.N. Molecular biology of oral cavity squamous cell carcinoma. Otolaryngol. Clin. North Am., 2006, 39(2), 229-247.
43. Kademani, D. Oral cancer. Mayo Clin. Proc., 2007, 82(7), 878-887. (Pubitemid 47015470)
44. Press, M.F.; Pike, M.C.; Hung, G.; Zhou, J. Y.; Ma, Y.; George, J.; Dietz-Band, J.; James, W.; Slamon, D.J.; Batsakis, J.G.; et al. Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis. Cancer Res., 1994, 54(21), 5675-5682. (Pubitemid 24346266)
45. Xia, W.; Lau, Y.K.; Zhang, H. Z.; Liu, A. R.; Li, L.; Kiyokawa, N.; Clayman, G. L.; Katz, R.L.; Hung, M.C. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin. Cancer Res., 1997, 3(1), 3-9. (Pubitemid 27079437)
46. Leeman-Neill, R.J.; Cai, Q.; Joyce, S.C.; Thomas, S.M.; Bhola, N.E.; Neill, D.B.; Arbiser, J.L.; Grandis, J.R. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin. Cancer Res., 2010, 16(9), 2571-2579.
47. Efferth, T.; Volm, M. Antibody-directed therapy of multidrugresistant tumor cells. Med. Oncol. Tumor Pharmacother., 1992, 9(1), 11-19.
48. Halatsch, M.E.; Gehrke, E.E.; Vougioukas, V.I.; Botefur, I.C.; ABorhani, F.; Efferth, T.; Gebhart, E.; Domhof, S.; Schmidt, U.; Buchfelder, M. Inverse correlation of epidermal growth factor receptor messenger RNA induction and suppression of anchorageindependent growth by OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in glioblastoma multiforme cell lines. J. Neurosurg., 2004, 100(3), 523-533. (Pubitemid 38269082)
49. Efferth, T.; Ramirez, T.; Gebhart, E.; Halatsch, M.E. Combination treatment of glioblastoma multiforme cell lines with the antimalarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol., 2004, 67(9), 1689-1700. (Pubitemid 38479847)
50. Efferth, T.; Sauerbrey, A.; Olbrich, A.; Gebhart, E.; Rauch, P.; Weber, H.O.; Hengstler, J.G.; Halatsch, M.E.; Volm, M.; Tew, K.D.; Ross, D.D.; Funk, J.O. Molecular modes of action of artesunate in tumor cell lines. Mol. Pharmacol., 2003, 64(2), 382-394. (Pubitemid 36910002)
51. Konkimalla, V.B.; McCubrey, J.A.; Efferth, T. The role of downstream signaling pathways of the epidermal growth factor receptor for Artesunate's activity in cancer cells. Curr. Cancer Drug Targets, 2009, 9(1), 72-80.
52. Zhou, W.; Ercan, D.; Chen, L.; Yun, C.H.; Li, D.; Capelletti, M.; Cortot, A.B.; Chirieac, L.; Iacob, R.E.; Padera, R.; Engen, J.R.; Wong, K.K.; Eck, M.J.; Gray, N.S.; Janne, P.A. Novel mutantselective EGFR kinase inhibitors against EGFR T790M. Nature, 2009, 462(7276), 1070-1074.
53. Konkimalla, V.B.; Efferth, T. Anti-cancer natural product library from traditional chinese medicine. Comb. Chem. High Throughput Screen., 2008, 11(1), 7-15.
54. Huang, R.L.; Chen, C.C.; Huang, Y. L.; Ou, J. C.; Hu, C.P.; Chen, C.F.; Chang, C. Anti-tumor effects of d-dicentrine from the root of Lindera megaphylla. Planta. Med., 1998, 64(3), 212-215.
55. Konkimalla, V.B.; Efferth, T. Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine. Biochem. Pharmacol., 2010, 79(8), 1092-1099.
56. Singh, F.; Gao, D.; Lebwohl, M.G.; Wei, H. Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett., 2003, 200(2), 115-121. (Pubitemid 38366091)
57. Kang, N.; Zhang, J.H.; Qiu, F.; Tashiro, S.I.; Onodera, S.; Ikejima, T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett., 2010, 294(2), 147-158.
58. Takai, N.; Ueda, T.; Nishida, M.; Nasu, K.; Narahara, H. Betahydroxyisovalerylshikonin has a profound anti-growth activity in human endometrial and ovarian cancer cells. Gynecol. Oncol., 2008, 109(1), 107-114.
59. Hashimoto, S.; Xu, Y.; Masuda, Y.; Aiuchi, T.; Nakajo, S.; Uehara, Y.; Shibuya, M.; Yamori, T.; Nakaya, K. Betahydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases. Jpn. J. Cancer Res., 2002, 93(8), 944-951. (Pubitemid 35012257)